Mentioned On
Episode Mentions
Pharma and BioTech Daily · Apr 29, 2026
AstraZeneca's Breztri Asthma Approval Boosts $80B Goal | Pharma and Biotech Daily
“JAK inhibitor achieved Phase 3 success in treating vitiligo, competing in differentiated JAK space”
FDA Drug Approval and RescissionData Integrity in Drug DevelopmentAI-Designed Therapeutics
View Analysis